Pressure Biosciences Inc
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formul… Read more
Pressure Biosciences Inc (PBIO) - Total Liabilities
Latest total liabilities as of June 2024: $44.11 Million USD
Based on the latest financial reports, Pressure Biosciences Inc (PBIO) has total liabilities worth $44.11 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pressure Biosciences Inc - Total Liabilities Trend (2000–2023)
This chart illustrates how Pressure Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pressure Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Pressure Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EUTELSAT COMM.
MU:E3B
|
Germany | €4.57 Billion |
|
Notoria
WAR:NTS
|
Poland | zł1.01 Million |
|
Khiron Life Sciences Corp
PINK:KHRNF
|
USA | $11.35 Million |
|
Eckoh Plc
LSE:ECK
|
UK | GBX12.93 Million |
|
BHB BRAUHOLDING
MU:B9B
|
Germany | €3.50 Million |
|
Gamer Pakistan Inc. Common Stock
PINK:GPAK
|
USA | $38.96K |
|
SDX Energy plc
PINK:SDXEF
|
USA | $31.88 Million |
Liability Composition Analysis (2000–2023)
This chart breaks down Pressure Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pressure Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pressure Biosciences Inc (2000–2023)
The table below shows the annual total liabilities of Pressure Biosciences Inc from 2000 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $33.80 Million | -2.57% |
| 2022-12-31 | $34.70 Million | +38.55% |
| 2021-12-31 | $25.04 Million | +30.29% |
| 2020-12-31 | $19.22 Million | +38.56% |
| 2019-12-31 | $13.87 Million | +62.71% |
| 2018-12-31 | $8.52 Million | -49.20% |
| 2017-12-31 | $16.78 Million | +67.68% |
| 2016-12-31 | $10.01 Million | +2.32% |
| 2015-12-31 | $9.78 Million | +157.16% |
| 2014-12-31 | $3.80 Million | +23.86% |
| 2013-12-31 | $3.07 Million | +6.12% |
| 2012-12-31 | $2.89 Million | +23.31% |
| 2011-12-31 | $2.35 Million | +200.51% |
| 2010-12-31 | $781.00K | +45.71% |
| 2009-12-31 | $536.00K | -26.68% |
| 2008-12-31 | $731.00K | -1.62% |
| 2007-12-31 | $743.00K | -68.23% |
| 2006-12-31 | $2.34 Million | -28.45% |
| 2005-12-31 | $3.27 Million | +152.43% |
| 2004-12-31 | $1.29 Million | -79.85% |
| 2003-12-31 | $6.43 Million | -10.93% |
| 2002-12-31 | $7.22 Million | -9.51% |
| 2001-12-31 | $7.97 Million | -46.12% |
| 2000-12-31 | $14.80 Million | -- |